65623-82-7

Usage

InChI:InChI=1/C12H14O4/c1-9(13)10-4-6-11(7-5-10)16-8-2-3-12(14)15/h4-7H,2-3,8H2,1H3,(H,14,15)

Upstream product

• 2969-81-5 Ethyl 4-bromobutyrate 
• 99-93-4 4-Hydroxyacetophenone 
• 5471-51-2 4-(4-hydroxyphenyl)-2-oxobutane 
• 174884-09-4 ethyl 2-(4-acetylphenoxy)butanoate 
• 174884-21-0 ethyl 4-(4-acetyl-2-methoxyphenoxy) butanoate 
• 74457-86-6 1-(2-fluoro-4-methoxyphenyl)-1-ethanone 
• 174884-35-6 ethyl 4-[2-chloro-4-formylphenoxy]butanoate 
• 174884-27-6 4-[4-(3-hydroxypropyl)phenoxy]butanoic acid, ethyl ester 
• 174884-25-4 4-(2-acetyl-5-methoxyphenoxy)butanoic acid, ethyl ester 
• 174884-12-9 4-(4-acetyl-2-methylphenoxy)butanoic acid, ethyl ester 

Downstream Products

• 65623-79-2 D,L-4-(4-acetylphenoxy)-2-phthalimidobutyric acid 
• 65623-97-4 methyl 4-(4-acetylphenoxy)butanoate 
• 1608463-44-0 C₂₀H₂₀N₄O₇ 
• 1609106-20-8 (2S,3Z)-5-{[(2R,3R,5S,6S)-6-{(2E,4E)-5-[(3R,4R,5R,7S)-7-(2-{(2E)-2-[1-(4-{4-[(2,5-dioxopyrrolidin-1-yl)oxy]-4-oxobutoxy}phenyl)ethylidene]hydrazinyl}-2-oxoethyl)-4-hydroxy-1,6-dioxaspiro[2.5]oct-5-yl]-3-methylpenta-2,4-dien-1-yl}-2,5-dimethyltetrahydro-2H-pyran-3-yl]amino}-5-oxopent-3-en-2-yl acetate 
• 1609106-19-5 4-{4-[(1E)-1-(2-{[(3R,5S,7R,8R)-7-{(1E,3E)-5-[(2S,3S,5R,6R)-5-{[(2Z,4S)-4-(acetyloxy)pent-2-enoyl]amino}-3,6-dimethyltetrahydro-2H-pyran-2-yl]-3-methylpenta-1,3-dien-1-yl}-8-hydroxy-1,6-dioxaspiro[2.5]oct-5-yl]acetyl}hydrazinylidene)ethyl]phenoxy}butanoic acid 
• 946528-65-0 (E)-4-(4-(1-(2-(3-mercapto-3-methylbutanoyl)hydrazono)ethyl)phenoxy)butanoic acid 
• 474970-05-3 4-(4-acetylphenyloxy)-N-[1-(3,4-dichlorobenzyl)piperidin-4-yl]butylamide 

Relevant academic research and scientific papers

Albumin-binding prodrugs via reversible iminoboronate forming nanoparticles for cancer drug delivery

Albumin-based nanomedicines are important nanoplatforms for cancer drug delivery. The drugs are either physically encapsulated or covalently conjugated to albumin or albumin-based nanosystems. Physical encapsulation is advantageous due to requiring no chemical modification of drug molecules, but many drugs, for instance, camptothecin (CPT) and curcumin (CCM), though very hydrophobic, can't be loaded in or form nanoformulations with albumin. Herein, we demonstrate prodrugs readily binding to proteins via iminoboronates and forming nanoparticles for cancer drug delivery. CPT and CCM were functionalized with 2-acetylphenylboronic acid (2-APBA) to produce prodrugs CPT-SS-APBA and CCM- APBA. The prodrugs bound to bovine serum albumin (BSA) via formation of iminoboronates and the produced BSA/prodrug readily self-assembled into well-defined nanoparticles with high loading efficiency, improved colloidal stability, and much-improved pharmacokinetics. The nanoparticles effectively released drugs in the intracellular acidic environment or the cytosol rich in glutathione (GSH). In vivo, the nanoparticles showed enhanced anticancer efficacy compared with clinically used irinotecan or sorafenib in subcutaneous 4 T1 or HepG2 tumor models. This work demonstrates a versatile protein-binding prodrug platform applicable to protein-based drug formulations and even antibody-drug conjugates.

Targeting cancer cells with folic acid-iminoboronate fluorescent conjugates

Herein we present the synthesis of fluorescent 2-acetylbenzeneboronic acids that undergo B-N promoted conjugation with lysozyme and N-(2-aminoethyl) folic acid (EDA-FA), generating conjugates that are selectively recognized and internalized by cancer cell

Enediyne derivatives useful for the synthesis of conjugates of methyltrithio antitumor agents

This invention describes carrier-drug conjugates prepared from disulfide analogs of the calicheamicin family of potent antitumor antibiotics and their derivatives, as well as similar analogs from related antitumor antibiotics such as the esperamicins. The carrier can be an antibody, growth factor, or steroid which targets an undesired population of cells, such as those of a tumor. Whole protein carriers as well as their antigen-recognizing fragments and their chemically or genetically manipulated counterparts are useful for the targeting portion of the conjugates. This invention includes compounds required for the synthesis of these conjugates, appropriate pharmaceutical compositions of the carrier-drug conjugates, and their method of use.